Crosstalk between ROR1 and the pre-B-Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

od Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Izdano 2012

HitWalker: variant prioritization for personalized functional cancer genomics

od Bottomly, Daniel, Wilmot, Beth, Tyner, Jeffrey W., Eide, Christopher A., Loriaux, Marc M., Druker, Brian J., McWeeney, Shannon K.
Izdano 2013

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine

od Bottomly, Daniel, Ryabinin, Peter A, Tyner, Jeffrey W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, McWeeney, Shannon K, Wilmot, Beth
Izdano 2013

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

od Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
izdano v Oncotarget (2015)

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

od Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.
Izdano 2010

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia

od Paiva, Cody, Rowland, Taylor A., Sreekantham, Bhargava, Godbersen, Claire, Best, Scott R., Kaur, Prabhjot, Loriaux, Marc M., Spurgeon, Stephen E.F., Danilova, Olga V., Danilov, Alexey V.
izdano v Haematologica (2017)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

od Burke, Russell T, Meadows, Sarah, Loriaux, Marc M, Currie, Kevin S., Mitchell, Scott A., Maciejewski, Patricia, Clarke, Astrid S., Dipaolo, Julie A., Druker, Brian J., Lannutti, Brian J., Spurgeon, Stephen E.
Izdano 2014

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

od Fleischman, Angela G., Maxson, Julia E., Luty, Samuel B., Agarwal, Anupriya, Royer, Lacey R., Abel, Melissa L., MacManiman, Jason D., Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Izdano 2013

RNAi screen for rapid therapeutic target identification in leukemia patients

od Tyner, Jeffrey W., Deininger, Michael W., Loriaux, Marc M., Chang, Bill H., Gotlib, Jason R., Willis, Stephanie G., Erickson, Heidi, Kovacsovics, Tibor, O'Hare, Thomas, Heinrich, Michael C., Druker, Brian J.
Izdano 2009

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

od Tyner, Jeffrey W., Erickson, Heidi, Deininger, Michael W. N., Willis, Stephanie G., Eide, Christopher A., Levine, Ross L., Heinrich, Michael C., Gattermann, Norbert, Gilliland, D. Gary, Druker, Brian J., Loriaux, Marc M.
Izdano 2009

Met receptor sequence variants R970C and T992I lack transforming capacity

od Tyner, Jeffrey W., Fletcher, Luke B., Wang, Ellen Q., Yang, Wayne F., Rutenberg-Schoenberg, Michael L., Beadling, Carol, Mori, Motomi, Heinrich, Michael C., Deininger, Michael W., Druker, Brian J., Loriaux, Marc M.
Izdano 2010

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

od Gozgit, Joseph M., Wong, Matthew J., Wardwell, Scott, Tyner, Jeffrey W., Loriaux, Marc M., Mohemmad, Qurish K., Narasimhan, Narayana I., Shakespeare, William C., Wang, Frank, Druker, Brian J., Clackson, Tim, Rivera, Victor M.
Izdano 2011

The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia

od Spurgeon, Stephen E., Coffey, Greg, Fletcher, Luke B., Burke, Russell, Tyner, Jeffrey W., Druker, Brian J., Betz, Andreas, DeGuzman, Francis, Pak, Yvonne, Baker, Dale, Pandey, Anjali, Hollenbach, Stanley J., Sinha, Uma, Loriaux, Marc M.
Izdano 2013

Therapeutically targetable ALK mutations in leukemia

od Maxson, Julia E., Davare, Monika A., Luty, Samuel B., Eide, Christopher A., Chang, Bill H., Loriaux, Marc M., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W.
izdano v Cancer Res (2015)

The Colony Stimulating Factor 3 Receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I

od Maxson, Julia E., Luty, Samuel B., MacManiman, Jason D., Paik, Jason C., Gotlib, Jason, Greenberg, Peter, Bahamadi, Swaleh, Savage, Samantha L., Abel, Melissa L., Eide, Christopher A., Loriaux, Marc M., Stevens, Emily A., Tyner, Jeffrey W.
izdano v Clin Cancer Res (2015)

An Adaptive Src-PDGFRA-Raf Axis in Rhabdomyosarcoma

od Abraham, Jinu, Chua, Ying Xuan, Glover, Jason M., Tyner, Jeffrey W., Loriaux, Marc M., Kilcoyne, Aoife, Giles, Francis J., Nelon, Laura D., Carew, Jennifer S., Ouyang, Yongjian, Michalek, Joel E., Pal, Ranadip, Druker, Brian J., Rubin, Brian P., Keller, Charles
Izdano 2012

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

od Lannutti, Brian J., Meadows, Sarah A., Herman, Sarah E. M., Kashishian, Adam, Steiner, Bart, Johnson, Amy J., Byrd, John C., Tyner, Jeffrey W., Loriaux, Marc M., Deininger, Mike, Druker, Brian J., Puri, Kamal D., Ulrich, Roger G., Giese, Neill A.
Izdano 2011

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression

od Beer, Philip A., Knapp, David J. H. F., Miller, Paul H., Kannan, Nagarajan, Sloma, Ivan, Heel, Kathy, Babovic, Sonja, Bulaeva, Elizabeth, Rabu, Gabrielle, Terry, Jefferson, Druker, Brian J., Loriaux, Marc M., Loeb, Keith R., Radich, Jerald P., Erber, Wendy N., Eaves, Connie J.
izdano v Blood (2015)

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

od Edwards V, David K., Sweeney, David Tyler, Ho, Hibery, Eide, Christopher A., Rofelty, Angela, Agarwal, Anupriya, Liu, Selina Qiuying, Danilov, Alexey V., Lee, Patrice, Chantry, David, McWeeney, Shannon K., Druker, Brian J., Tyner, Jeffrey W., Spurgeon, Stephen E., Loriaux, Marc M.
izdano v Oncotarget (2018)

TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics

od Zhong, Jun, Kim, Min-Sik, Chaerkady, Raghothama, Wu, Xinyan, Huang, Tai-Chung, Getnet, Derese, Mitchell, Christopher J., Palapetta, Shyam M., Sharma, Jyoti, O'Meally, Robert N., Cole, Robert N., Yoda, Akinori, Moritz, Albrecht, Loriaux, Marc M., Rush, John, Weinstock, David M., Tyner, Jeffrey W., Pandey, Akhilesh
Izdano 2012